Results suggest that alteration of gut microbiome with probiotics may become preventative strategy for patients
((An electron micrograph of a prostatic cancer cell. Photo: Reuters))**
Alteration of the gut microbiome with probiotics may help prevent and treat bowel cancer by reducing inflammation and suppressing colon tumours, a study in mice suggests.
Researchers at Baylor College of Medicine, Texas Children's Hospital and Columbia University in the US found that administration of histamine-generating gut microbes reduced inflammation and tumour formation in mice which lacked that ability to produce histamine on their own.
These results suggest that alteration of the gut microbiome with probiotics may become a new preventative or therapeutic strategy for patients at risk for colorectal cancer associated with inflammatory bowel disease.
"We are on the cusp of harnessing advances in microbiome science - the study of the microbes living in our body - that would facilitate diagnosis and treatment of human disease," said James Versalovic, Professor at Baylor College of Medicine.
"By simply applying diet-based cancer prevention strategies, such as supplementing microbes that provide missing life substances, we can potentially reduce the risk of cancer," said Versalovic.
Previous studies had shown that histamine, a chemical produced by the body that is well-known for its role in allergic disease, also may have a potential antitumour effect.
In the new study, researchers investigated whether the probiotic L reuteri 6475, which is able to generate histamine, had the ability to reduce the frequency and severity of inflammation-associated colorectal cancer in mice that were not able to produce histamine on their own.
The researchers conducted a series of experiments using mice that were deficient in histidine decarboxylase, the enzyme required to convert L-histidine to histamine.
Experimental mice were orally administered L reuteri 6475, which has the gene for histidine decarboxylase to produce histamine; control animals received L reuteri that lacked the gene to produce histidine decarboxylase.
The probiotic was administered both before and after the mice received a single treatment to induce tumour formation.
Fifteen weeks later, the mice were sacrificed and the tissues removed for study.
The animals treated with L reuteri 6475 showed increased expression of bacterial histidine decarboxylase enzyme and of the amount of histamine in their colons.
Positron emission tomography (PET) used to visualise the tumours showed that these mice had fewer and smaller tumours than control mice.
L reuteri strains deficient in histidine decarboxylase activity did not provide protective effects; the mice showed increased numbers of "hot spots" indicative of tumour formation, researchers said.
Treatment with the histamine-generating probiotic also reduced inflammatory responses typically associated with increased risk of tumour development.
"These observations are consistent with the conclusion that histamine-generating probiotic L reuteri may attenuate development of colorectal cancer in the animal model, at least in part, via reduction of a pro-cancer inflammatory response," said Versalovic.